We hypothesized that compositions after chronic SD could disrupt the intestinal mucosal barrier by activating the NLRP3 inflammasome in the gut and initiate intestinal and peripheral inflammatory responses, which, in turn, could lead to NLRP3-controlled neuroinflammation in the central nervous system (CNS) and ultimately lead to cognitive impairment. The gene discussed is NLRP3; the disease is Cognitive impairment.